Nektar Historical Income Statement

NKTR Stock

USD 1.14 0.01 0.88%

Historical analysis of Nektar Therapeutics income statement accounts such as Gross Profit of 50.8 M can show how well Nektar Therapeutics performed in making a profits. Evaluating Nektar Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Nektar Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Nektar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nektar Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

About Nektar Income Statement Analysis

Nektar Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Nektar Therapeutics shareholders. The income statement also shows Nektar investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Nektar Therapeutics Income Statement Chart

At this time, Nektar Therapeutics' Total Revenue is relatively stable compared to the past year. As of 11/30/2024, Other Operating Expenses is likely to grow to about 258 M, while Interest Expense is likely to drop slightly above 23.9 M.

Total Revenue Gross Profit Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Nektar Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Nektar Therapeutics minus its cost of goods sold. It is profit before Nektar Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Nektar Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Nektar Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.At this time, Nektar Therapeutics' Total Revenue is relatively stable compared to the past year. As of 11/30/2024, Other Operating Expenses is likely to grow to about 258 M, while Interest Expense is likely to drop slightly above 23.9 M.

	2021	2022	2023	2024 (projected)
Gross Profit	77.0M	70.4M	53.5M	50.8M
Total Revenue	101.9M	92.1M	90.1M	162.3M

Gross Profit Total Revenue

Nektar Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		0.45	-0.07	-0.05	0.52	-0.37	-0.31	-0.27	0.06	0.52	-0.29	0.29	-0.29	0.1	0.54	0.37	-0.25	0.56	0.19	-0.23	0.31	0.38	0.07	0.2	0.22
Interest Expense	0.45		0.34	0.34	0.75	-0.07	-0.02	0.0	0.58	0.72	-0.06	0.07	-0.06	0.22	0.73	0.53	0.02	0.23	0.71	-0.2	-0.18	0.1	0.06	0.2	0.25
Total Revenue	-0.07	0.34		1.0	0.39	0.84	0.84	0.85	0.1	0.38	0.83	0.21	0.83	0.18	0.43	0.15	0.86	0.48	0.28	0.04	0.15	0.37	-0.35	0.22	0.09
Gross Profit	-0.05	0.34	1.0		0.39	0.84	0.85	0.86	0.07	0.39	0.84	0.25	0.84	0.19	0.43	0.16	0.87	0.51	0.26	-0.01	0.17	0.34	-0.3	0.2	0.17
Other Operating Expenses	0.52	0.75	0.39	0.39		-0.17	-0.15	-0.13	0.14	1.0	-0.17	-0.08	-0.17	0.27	0.99	0.89	-0.1	0.41	0.57	-0.06	-0.2	0.43	-0.16	0.65	0.17
Operating Income	-0.37	-0.07	0.84	0.84	-0.17		0.99	0.99	0.02	-0.18	0.99	0.29	0.99	0.05	-0.13	-0.35	0.98	0.28	-0.05	0.05	0.29	0.12	-0.26	-0.16	0.04
Ebit	-0.31	-0.02	0.84	0.85	-0.15	0.99		1.0	0.01	-0.15	1.0	0.42	1.0	0.04	-0.09	-0.37	1.0	0.37	-0.08	-0.09	0.34	0.05	-0.14	-0.24	0.15
Ebitda	-0.27	0.0	0.85	0.86	-0.13	0.99	1.0		0.01	-0.13	1.0	0.44	1.0	0.04	-0.06	-0.36	1.0	0.4	-0.07	-0.1	0.36	0.07	-0.14	-0.23	0.16
Cost Of Revenue	0.06	0.58	0.1	0.07	0.14	0.02	0.01	0.01		0.08	-0.03	-0.15	-0.03	0.16	0.07	0.1	0.05	-0.33	0.51	0.13	-0.14	-0.03	-0.15	-0.09	-0.17
Total Operating Expenses	0.52	0.72	0.38	0.39	1.0	-0.18	-0.15	-0.13	0.08		-0.17	-0.07	-0.17	0.26	0.99	0.89	-0.1	0.44	0.54	-0.07	-0.2	0.44	-0.15	0.66	0.18
Income Before Tax	-0.29	-0.06	0.83	0.84	-0.17	0.99	1.0	1.0	-0.03	-0.17		0.43	1.0	0.03	-0.11	-0.39	0.99	0.38	-0.11	-0.08	0.37	0.07	-0.15	-0.23	0.14
Total Other Income Expense Net	0.29	0.07	0.21	0.25	-0.08	0.29	0.42	0.44	-0.15	-0.07	0.43		0.43	0.0	0.02	-0.42	0.42	0.61	-0.43	-0.85	0.63	-0.38	0.64	-0.64	0.67
Net Income	-0.29	-0.06	0.83	0.84	-0.17	0.99	1.0	1.0	-0.03	-0.17	1.0	0.43		0.02	-0.11	-0.39	0.99	0.38	-0.11	-0.08	0.37	0.07	-0.15	-0.23	0.14
Income Tax Expense	0.1	0.22	0.18	0.19	0.27	0.05	0.04	0.04	0.16	0.26	0.03	0.0	0.02		0.24	0.28	0.07	-0.06	0.19	0.2	-0.15	0.01	0.09	0.13	0.35
Research Development	0.54	0.73	0.43	0.43	0.99	-0.13	-0.09	-0.06	0.07	0.99	-0.11	0.02	-0.11	0.24		0.83	-0.04	0.5	0.52	-0.13	-0.15	0.42	-0.1	0.61	0.2
Selling General Administrative	0.37	0.53	0.15	0.16	0.89	-0.35	-0.37	-0.36	0.1	0.89	-0.39	-0.42	-0.39	0.28	0.83		-0.33	0.1	0.54	0.22	-0.36	0.46	-0.33	0.82	0.02
Net Income From Continuing Ops	-0.25	0.02	0.86	0.87	-0.1	0.98	1.0	1.0	0.05	-0.1	0.99	0.42	0.99	0.07	-0.04	-0.33		0.39	-0.06	-0.08	0.36	0.09	-0.16	-0.21	0.15
Non Operating Income Net Other	0.56	0.23	0.48	0.51	0.41	0.28	0.37	0.4	-0.33	0.44	0.38	0.61	0.38	-0.06	0.5	0.1	0.39		0.0	-0.48	0.45	0.33	0.15	0.03	0.45
Non Recurring	0.19	0.71	0.28	0.26	0.57	-0.05	-0.08	-0.07	0.51	0.54	-0.11	-0.43	-0.11	0.19	0.52	0.54	-0.06	0.0		0.3	-0.39	0.38	-0.35	0.46	-0.13
Tax Provision	-0.23	-0.2	0.04	-0.01	-0.06	0.05	-0.09	-0.1	0.13	-0.07	-0.08	-0.85	-0.08	0.2	-0.13	0.22	-0.08	-0.48	0.3		-0.39	0.58	-0.81	0.59	-0.71
Interest Income	0.31	-0.18	0.15	0.17	-0.2	0.29	0.34	0.36	-0.14	-0.2	0.37	0.63	0.37	-0.15	-0.15	-0.36	0.36	0.45	-0.39	-0.39		0.09	0.12	-0.27	0.21
Net Interest Income	0.38	0.1	0.37	0.34	0.43	0.12	0.05	0.07	-0.03	0.44	0.07	-0.38	0.07	0.01	0.42	0.46	0.09	0.33	0.38	0.58	0.09		-0.81	0.78	-0.48
Reconciled Depreciation	0.07	0.06	-0.35	-0.3	-0.16	-0.26	-0.14	-0.14	-0.15	-0.15	-0.15	0.64	-0.15	0.09	-0.1	-0.33	-0.16	0.15	-0.35	-0.81	0.12	-0.81		-0.72	0.74
Extraordinary Items	0.2	0.2	0.22	0.2	0.65	-0.16	-0.24	-0.23	-0.09	0.66	-0.23	-0.64	-0.23	0.13	0.61	0.82	-0.21	0.03	0.46	0.59	-0.27	0.78	-0.72		-0.39
Selling And Marketing Expenses	0.22	0.25	0.09	0.17	0.17	0.04	0.15	0.16	-0.17	0.18	0.14	0.67	0.14	0.35	0.2	0.02	0.15	0.45	-0.13	-0.71	0.21	-0.48	0.74	-0.39

Click cells to compare fundamentals

Nektar Therapeutics Account Relationship Matchups

Nektar Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	59.5M	12.5M	13M	12.2M	7.8M	7.4M
Interest Expense	46.4M	37.1M	47.3M	28.9M	25.3M	23.9M
Total Revenue	114.6M	152.9M	101.9M	92.1M	90.1M	162.3M
Gross Profit	93.2M	133.4M	77.0M	70.4M	53.5M	50.8M
Other Operating Expenses	554.7M	532.8M	548.0M	332.3M	227.5M	258.0M
Operating Income	(440.0M)	(379.9M)	(446.1M)	(240.2M)	(137.4M)	(144.3M)
Ebit	(440.0M)	(406.8M)	(476.0M)	(336.1M)	(250.9M)	(238.4M)
Ebitda	(380.5M)	(394.3M)	(463.0M)	(323.9M)	(243.1M)	(231.0M)
Cost Of Revenue	21.4M	19.5M	24.9M	21.6M	36.6M	26.8M
Total Operating Expenses	533.3M	513.4M	523.1M	310.7M	190.9M	228.8M
Income Before Tax	(440.1M)	(443.9M)	(523.3M)	(365.0M)	(276.3M)	(262.4M)
Total Other Income Expense Net	(19K)	(64.0M)	(77.2M)	(124.7M)	(138.8M)	(131.9M)
Net Income	(440.7M)	(444.4M)	(523.8M)	(368.2M)	(276.1M)	(262.3M)
Income Tax Expense	613K	493K	557K	3.2M	(200K)	(190K)
Research Development	434.6M	408.7M	400.3M	218.3M	114.2M	184.6M
Selling General Administrative	98.7M	104.7M	122.8M	92.3M	77.4M	52.5M
Net Income From Continuing Ops	(440.7M)	(444.4M)	(523.8M)	(368.2M)	(293.7M)	(279.0M)
Non Operating Income Net Other	37.6M	46.3M	18.3M	(29.9M)	(34.3M)	(32.6M)
Net Income Applicable To Common Shares	(440.7M)	(444.4M)	(523.8M)	(368.2M)	(331.4M)	(314.8M)
Tax Provision	613K	493K	557K	3.2M	3.0M	3.1M
Interest Income	46.3M	18.3M	2.6M	6.7M	17.6M	15.4M
Net Interest Income	(19K)	(18.8M)	(44.7M)	(22.2M)	(8.1M)	(8.5M)
Reconciled Depreciation	13.2M	14.2M	14.1M	13.0M	9.3M	10.2M

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Nektar Stock

0.47	AVAL	Grupo Aval	Pair Corr
0.35	FNMFO	Federal National Mortgage	Pair Corr

The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.

The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nektar Historical Income Statement

About Nektar Income Statement Analysis

Nektar Therapeutics Income Statement Chart

Total Revenue

Gross Profit

Total Operating Expenses

Nektar Therapeutics income statement Correlations

Nektar Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nektar Therapeutics income statement Accounts

Pair Trading with Nektar Therapeutics

Moving against Nektar Stock

Additional Tools for Nektar Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Ebit

Tax Provision	- 0.85	Total Other Income Expense Net
Reconciled Depreciation	- 0.81	Net Interest Income
Reconciled Depreciation	- 0.81	Tax Provision
Extraordinary Items	- 0.72	Reconciled Depreciation
Selling And Marketing Expenses	- 0.71	Tax Provision
Extraordinary Items	- 0.64	Total Other Income Expense Net